

**TABLE 201: RELAPSE**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-2	1	(6) SOF12 + LDV12	7	109	6%
		(7) SOF24 + LDV24	0	109	0%
		(10) SOF12 + LDV12 + RBV12	4	111	4%
		(11) SOF24 + LDV24 + RBV24	0	111	0%
Andreone et al., 2014 PEARL-II	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	95	0%
Bacon et al., 2011 RESPOND2	1	(1) PR48	8	80	10%
		(74) B32 PR36-48 RGT	17	162	10%
Bourlière et al., 2015 SIRIUS	1	(7) SOF24 + LDV24	2	77	3%
		(10) SOF12 + LDV12 + RBV12	3	77	4%
Dieterich et al., 2014-2+3+4	1	(69) SIM12 PR24-48 RGT or SIM12 PR48	4	53	8%
Forns et al., 2015 C-SALVAGE	1	(23) GRZ12 + ELB12 + RBV12	3	79	4%
Gane et al., 2013-2 ELECTRON	1	(3) SOF12 + RBV12	9	10	90%
Gane et al., 2014-2 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Gane et al., 2014-3 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	9	0%
Forns et al., PROMISE	1	(1) PR48	45	133	34%
		(42) SIM12 PR24-48 RGT	46	260	18%
Jacobson et al., 2013 FUSION	2+3	(3) SOF12 + RBV12	7	103	7%
Jensen et al., 2015-1 HALLMARK-QUAD	1+4	(18) DCV24 + ASU24 + PR24	8	354	2%
		(18) DCV24 + ASU24 + PR24	0	44	0%
Kumada et al., 2014	1b	(17) DCV24 + ASU24	6	87	7%
Lawitz et al., 2014	2+3	(40) SOF12 + PR12	2	47	4%
Lawitz et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12(50 mg q.d.)	3	33	9%
		(59) GRZ18 + ELB18 (50 mg q.d.)	0	32	0%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	0	32	0%
		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	0	33	0%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	1	19	5%
		(10) SOF12 + LDV12 + RBV12	0	21	0%
Lok et al., 2014 DUAL A2	1	(17) DCV24 + ASU24	1	20	5%
		(18) DCV24 + ASU24 + PR24	1	21	5%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	7	205	3%
Mizokami et al., 2015-1	1	(10) SOF12 + LDV12 + RBV12	0	88	0%
Mizokami et al., 2015-2	1	(10) SOF12 + LDV12 + RBV12	0	87	0%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Molina et al., 2015 PHOTON-2	2+3	(4) SOF24 + RBV24	6	48	13%
Muir et al., 2015 UNITY-2	3	(25) DCV12 + ASU12 + BEC12 + RBV12	1	45	2%
		(26) DCV12 + ASU12 + BEC12	5	45	11%
Nelson D. et al., 2015 ALLY-3	3	(19) DCV12 + SOF12	7	51	14%
Omata et al., 2014	2	(3) SOF12 + RBV12	3	63	5%
Osinusi et al., 2014 SYNERGY	1	(6) SOF12 + LDV12	0	14	0%
Pearlman et al., 2015	1	(5) SIM12 + SOF12	3	36	8%
		(40) SOF12 + PR12	2	14	14%
Pol et al., 2015	1	(40) SOF12 + PR12	17	80	21%
Poordad et al., 2015 UNITY-1	1	(26) DCV12 + ASU12 + BEC12	6	103	6%
Reddy et al., 2015 ATTAIN	1	(39) T12 PR48 q8	43	384	11%
		(68) SIM12 PR48	43	379	11%
Ruane et al., 2014	4	(3) SOF12 + RBV12	7	17	41%
		(4) SOF24 + RBV24	2	15	13%
Sulkowski et al., 2014-3	3	(4) SOF24 + RBV24	1	17	6%
Wyles et al., 2015	1	(10) SOF12 + LDV12 + RBV12	1	51	2%
Zeuzem et al., 2014 ASPIRE	1	(68) SIM12 PR48	6	66	9%
		(1) PR48	12	66	18%
Zeuzem et al., 2011 REALIZE	1	(1) PR48	28	132	21%
		(39) T12 PR48 q8	10	266	4%
Zeuzem et al., 2014 SAPPHIRE-II	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	7	297	2%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q.d. = once daily; RBV = ribavirin; RIT = ritonavir; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir.  
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.